Irinotecan, Gemcitabine, Chemotherapy for Biliary Tract Cancer
NCT ID: NCT00832689
Last Updated: 2011-03-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
39 participants
INTERVENTIONAL
2008-06-30
2010-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma
NCT06903273
A Phase I Study of Adjuvant Chemotherapy With GS in Biliary Tract Cancer Undergoing Resection Without Major Hepatectomy
NCT01713387
Phase I Study of Gemcitabine or S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer
NCT01291615
Irinotecan Liposomes +5-FU/LV Versus Capecitabine in Patients of Recurrence After Resection of Resectable BTC
NCT06699459
Gemcitabine and S-1 for Advanced Biliary Tract Cancer
NCT02146703
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Irinotecan and Gemcitabine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Irinotecan and Gemcitabine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age: 18 \~75 years old
* Performance status: ECOG 0-2
* Hematopoietic:
* Granulocyte count at least 1,500/mm3
* Platelet count at least 100,000/mm3
* Hepatic:
* Bilirubin No greater than 2 fold the upper normal limit
* AST/ALT : No greater than 3 fold the upper normal limit
* Renal:
* Creatinine - no greater than 1.5 mg/dL
* Not pregnant
* No other serious medical or psychiatric illness that would preclude giving informed consent or limit
* No prior chemotherapy within 6 months
* No other concurrent anticancer radiotherapy within 6 months
17 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yonsei University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Severance hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jeong Youp Park, MD
Role: STUDY_DIRECTOR
Assistant professor of division of Gastroenterology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Severance hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
4-2007-0191
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.